Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 425, pseudogene (RNU6-425P) is a pseudogene of the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a highly conserved non-coding RNA essential for the catalytic function of the spliceosome, the machine responsible for pre-mRNA splicing in eukaryotes[1][3]. However, RNU6-425P itself is annotated as a pseudogene, meaning it resembles a functional U6 snRNA gene but harbors sequence changes (often including mutations, truncations, or insertion/deletion events) that prevent its transcription into a functional snRNA product or its participation in the spliceosome[5]. There is no evidence that RNU6-425P is a protein-coding gene or involved in any enzymatic or receptor-mediated biological process. Most U6 snRNA pseudogenes are considered non-functional remnants of gene duplication events, although in rare cases some pseudogenes elsewhere in the genome can serve as regulatory RNAs[2]; there is currently no such evidence for RNU6-425P specifically. Key contextual notes: - U6 snRNA itself is a key spliceosomal RNA that forms part of the active site for pre-mRNA splicing, but the 425th member annotated here (RNU6-425P) is a pseudogene form, not a functional U6 or direct participant in splicing[5]. - There are many U6 snRNA pseudogenes in the human genome, and annotation "pseudogene" indicates non-functionality in canonical RNA processing[3][5]. - No known drugs, biomarkers, or therapeutic safety information is associated with this specific pseudogene. - There is nothing obviously wrong with the provided name or identifier; it is correctly annotated as a pseudogene and not a therapeutic target. If you require information about the functional U6 snRNA, see core references above regarding its essential role in the spliceosome[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 425, pseudogene (RNU6-425P).